Discovery of nanomolar ligands with novel scaffolds for the histamine H4 receptor by virtual screening. Levoin N, Labeeuw O, Billot X, Calmels T, Danvy D, Krief S, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC. 0624 Anticataplectic Efficacy of Pitolisant, the First Potent and Highly Selective Histamine H3-Receptor Antagonist/Inverse Agonist Sleep. Thorpy M, Schwartz J, Lecomte J, Caussé C, Dayno JM. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. PMID 31626696 DOI: 10.1093/Sleep/Zsz252ĭauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC.
Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC. Pharmacokinetics of pitolisant in children and adolescents with narcolepsy. Lecendreux M, Plazzi G, Franco P, Jacqz-Aigrain E, Robert P, Duvauchelle T, Schwartz JC. Exploring Occupancy of the Histamine H3 Receptor by Pitolisant in Humans Using Positron Emission Tomography. Rusjan PM, Sabioni P, Di Ciano P, Mansouri E, Boileau I, Laveillé A, Capet M, Duvauchelle T, Schwartz JC, Robert P, Le Foll B.
0 kommentar(er)
